Source: BioSpace

LogicBio: LogicBio Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business UpdatesFDA Clears IND Application for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients

- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today reported financial results for the quarter ended June 30, 2020, provided a business update and announced the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for LB-001 for the treatment of methylmalonic

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Frederic Chereau's photo - President & CEO of LogicBio

President & CEO

Frederic Chereau

CEO Approval Rating


LogicBio is a biotechnology company that develops genetic medicines to treat rare pediatric diseases. Read more